ID: ALA1668935

Max Phase: Preclinical

Molecular Formula: C17H29N3O3S

Molecular Weight: 355.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  CS(=O)(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1

Standard InChI:  InChI=1S/C17H29N3O3S/c1-24(22,23)20-4-2-15(3-5-20)18-16(21)19-17-9-12-6-13(10-17)8-14(7-12)11-17/h12-15H,2-11H2,1H3,(H2,18,19,21)

Standard InChI Key:  DBPGHZGPUBWOQS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 355.50

Molecular Weight (Monoisotopic): 355.1930

AlogP: 1.68

#Rotatable Bonds: 3

Polar Surface Area: 78.51

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.32

CX LogP: -0.08

CX LogD: -0.08

Aromatic Rings: 0

Heavy Atoms: 24

QED Weighted: 0.81

Np Likeness Score: -1.51

References

1. Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do ZN, Mehra U, Tran V, Vincelette J, Waszczuk J, White K, Wong KR, Zhang LN, Jones PD, Hammock BD, Patel DV, Whitcomb R, MacIntyre DE, Sabry J, Gless R..  (2011)  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.,  21  (3): [PMID:21211973] [10.1016/j.bmcl.2010.12.042]

2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

3.  (2013)  Conformationally restricted urea inhibitors of soluble epoxide hydrolase, 

Source

Source(3):

• Scientific Literature
• AstraZeneca Deposited Data
• BindingDB Database